FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108416273> ?p ?o ?g. }

• W3108416273 endingPage "34" @default.
• W3108416273 startingPage "26" @default.
• W3108416273 abstract "Hepatitis A virus (HAV) remains a global public health concern, which is potentially growing in Latin America, due to an expected shift from high to intermediate endemicity levels. The use of HAV vaccines in pediatric national immunization programs (NIPs), either as a 2-dose or a 1-dose schedule, has been explored in Latin American countries; however, evidence demonstrating long-term protection in this population is limited in the region. We evaluated long-term antibody persistence following a 1-dose partial series and the recommended 2-dose schedule used in Panama’s pediatric NIP. Two independent cross-sectional serological surveys were conducted at year 8 (Y8) and Y10 following vaccination under the NIP with 1 or 2 doses of an inactivated HAV vaccine (Havrix, GSK). Seropositivity (anti-HAV antibody concentration ≥ 15 mIU/mL) rates and antibody geometric mean concentrations (GMCs) were assessed at each serosurvey. Non-inferiority of 1 dose versus 2 doses was also explored. This study (NCT02712359) included 600 and 599 children at Y8 and Y10 post-vaccination, respectively. Seropositivity rates were 74.3% (95% confidence interval [CI]: 69.0; 79.2) and 97.7% (95% CI: 95.3; 99.1) at Y8 and 71.9% (95% CI: 66.4; 76.9) and 96.3% (95% CI: 93.5; 98.2) at Y10, in the 1-dose and 2-dose groups, respectively. Antibody GMCs were lower in the 1-dose versus the 2-dose group in both surveys. Non-inferiority was not demonstrated since the lower limit of the 2-sided 95% CI for the between-group difference in seropositivity rates (1-dose minus 2-dose) was < −10%. Anti-HAV antibody persistence was observed in lower percentages of children receiving 1 dose versus 2 doses of Havrix, at 8 and 10 years post-vaccination in Panama. Further investigations are needed to confirm antibody persistence and conclude on the protection afforded beyond 10 years in the pediatric population in Latin America." @default.
• W3108416273 created "2020-12-07" @default.
• W3108416273 creator A5000820903 @default.
• W3108416273 creator A5001013986 @default.
• W3108416273 creator A5018208220 @default.
• W3108416273 creator A5025089313 @default.
• W3108416273 creator A5040295623 @default.
• W3108416273 creator A5054523586 @default.
• W3108416273 creator A5056547895 @default.
• W3108416273 creator A5058702565 @default.
• W3108416273 creator A5064439013 @default.
• W3108416273 creator A5091734916 @default.
• W3108416273 date "2021-01-01" @default.
• W3108416273 modified "2023-10-18" @default.
• W3108416273 title "Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama" @default.
• W3108416273 cites W163485410 @default.
• W3108416273 cites W1967963754 @default.
• W3108416273 cites W1974678096 @default.
• W3108416273 cites W1976334281 @default.
• W3108416273 cites W1977295761 @default.
• W3108416273 cites W1980646536 @default.
• W3108416273 cites W1980973298 @default.
• W3108416273 cites W1983460139 @default.
• W3108416273 cites W1988605508 @default.
• W3108416273 cites W1992911899 @default.
• W3108416273 cites W1994775354 @default.
• W3108416273 cites W2020461577 @default.
• W3108416273 cites W2035047403 @default.
• W3108416273 cites W2037099233 @default.
• W3108416273 cites W2056572981 @default.
• W3108416273 cites W2058371783 @default.
• W3108416273 cites W2059291557 @default.
• W3108416273 cites W2062192870 @default.
• W3108416273 cites W2063665719 @default.
• W3108416273 cites W2065780680 @default.
• W3108416273 cites W2068099587 @default.
• W3108416273 cites W2069377983 @default.
• W3108416273 cites W2082184261 @default.
• W3108416273 cites W2087489631 @default.
• W3108416273 cites W2093800471 @default.
• W3108416273 cites W2094180390 @default.
• W3108416273 cites W2215494520 @default.
• W3108416273 cites W2340989136 @default.
• W3108416273 cites W2500901575 @default.
• W3108416273 cites W2514724361 @default.
• W3108416273 cites W2518681880 @default.
• W3108416273 cites W2546032912 @default.
• W3108416273 cites W2612034434 @default.
• W3108416273 cites W2759116895 @default.
• W3108416273 cites W276395371 @default.
• W3108416273 cites W2770961252 @default.
• W3108416273 cites W2792780083 @default.
• W3108416273 cites W2800812255 @default.
• W3108416273 cites W2909598744 @default.
• W3108416273 cites W2913017242 @default.
• W3108416273 cites W4232295757 @default.
• W3108416273 cites W918737270 @default.
• W3108416273 doi "https://doi.org/10.1016/j.vaccine.2020.11.030" @default.
• W3108416273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33239226" @default.
• W3108416273 hasPublicationYear "2021" @default.
• W3108416273 type Work @default.
• W3108416273 sameAs 3108416273 @default.
• W3108416273 citedByCount "3" @default.
• W3108416273 countsByYear W31084162732022 @default.
• W3108416273 countsByYear W31084162732023 @default.
• W3108416273 crossrefType "journal-article" @default.
• W3108416273 hasAuthorship W3108416273A5000820903 @default.
• W3108416273 hasAuthorship W3108416273A5001013986 @default.
• W3108416273 hasAuthorship W3108416273A5018208220 @default.
• W3108416273 hasAuthorship W3108416273A5025089313 @default.
• W3108416273 hasAuthorship W3108416273A5040295623 @default.
• W3108416273 hasAuthorship W3108416273A5054523586 @default.
• W3108416273 hasAuthorship W3108416273A5056547895 @default.
• W3108416273 hasAuthorship W3108416273A5058702565 @default.
• W3108416273 hasAuthorship W3108416273A5064439013 @default.
• W3108416273 hasAuthorship W3108416273A5091734916 @default.
• W3108416273 hasBestOaLocation W31084162731 @default.
• W3108416273 hasConcept C126322002 @default.
• W3108416273 hasConcept C159654299 @default.
• W3108416273 hasConcept C187212893 @default.
• W3108416273 hasConcept C203014093 @default.
• W3108416273 hasConcept C22070199 @default.
• W3108416273 hasConcept C2775876817 @default.
• W3108416273 hasConcept C2776029263 @default.
• W3108416273 hasConcept C2780801004 @default.
• W3108416273 hasConcept C2908647359 @default.
• W3108416273 hasConcept C44249647 @default.
• W3108416273 hasConcept C45189115 @default.
• W3108416273 hasConcept C71924100 @default.
• W3108416273 hasConcept C99454951 @default.
• W3108416273 hasConceptScore W3108416273C126322002 @default.
• W3108416273 hasConceptScore W3108416273C159654299 @default.
• W3108416273 hasConceptScore W3108416273C187212893 @default.
• W3108416273 hasConceptScore W3108416273C203014093 @default.
• W3108416273 hasConceptScore W3108416273C22070199 @default.
• W3108416273 hasConceptScore W3108416273C2775876817 @default.
• W3108416273 hasConceptScore W3108416273C2776029263 @default.
• W3108416273 hasConceptScore W3108416273C2780801004 @default.

• next